NCT00613171View on ClinicalTrials.gov

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 2, 2008

Primary Completion Date

January 13, 2010

Study Completion Date

January 13, 2010

Conditions
Systemic Sclerosis, Scleroderma
Interventions
DRUG

STI571

STI571 tablets taken orally once a day

Trial Locations (7)

21224

Novartis Investigator Site, Baltimore

60611

Novartis Investigator Site, Chicago

02118

Novartis Investigator Site, Boston

Unknown

Novartis Investigator Site, Erlangen

Novartis Investigator Site, Florence

Novartis Investigator Site, Zurich

Novartis Investigator Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00613171 - Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis | Biotech Hunter | Biotech Hunter